Seagen se­cures a speedy FDA re­view on Tukysa as Mer­ck buy­out talks re­port­ed­ly stall

Af­ter ru­mors of stalled buy­out talks be­tween Mer­ck and Seagen, per­haps a new Tukysa in­di­ca­tion could reignite in­ter­est.

The FDA has grant­ed Tukysa a pri­or­i­ty re­view in com­bi­na­tion with Genen­tech’s Her­ceptin for sec­ond-line HER2-pos­i­tive metasta­t­ic col­orec­tal can­cer, the com­pa­ny re­vealed on Mon­day. The de­ci­sion comes just a cou­ple of months af­ter Seagen un­corked the full Phase II re­sults at ES­MO, boast­ing a no­table im­prove­ment in over­all sur­vival from the last read­out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER